Company intelligence / Profile preview
EpiPharm AG
Binningen, Basel-Landschaft, Switzerlandepipharm.ch ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
EpiPharm AG is a clinical-stage biopharmaceutical company developing innovative, non-invasive, take-home topical products for the treatment of benign skin tumors and hyperpigmentation disorders. Its lead product, EPI-SK17, targets the underlying causes of seborrheic keratosis. The company focuses on solutions that can be used at home and are non-invasive alternatives to current treatments.[1][2] No detailed clinical results are publicly available.
- Therapeutic areas
- Dermatology
- Modalities
- Topical therapiesNon-invasive products
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Not explicitly listed; open to collaborations per website contact section.[4]
Beyond the preview
Go deeper on EpiPharm AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiPharm AG.